New drug targets tough cancers with KRAS G12D mutation

NCT ID NCT07483983

Recruiting now Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests a new drug called ASP3082 in 60 people with advanced lung or pancreatic cancer that has a specific gene change (KRAS G12D). Participants receive the drug intravenously once a week in 21-day cycles. The main goal is to see how well the drug shrinks tumors and to understand why some cancers stop responding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC/LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC/LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER METASTATIC/LOCALLY PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Centre Georges François Leclerc
RECRUITING

Dijon, France
Gustave Roussy
RECRUITING

Villejuif, France, 94800, France
Hôpital Paris Saint-Joseph
RECRUITING

Paris, France
Institut Bergonié
RECRUITING

Bordeaux, France
Institut Paoli Calmettes
NOT_YET_RECRUITING

Marseille, France
Institut de Cancérologie de Lorraine
RECRUITING

Vandœuvre-lès-Nancy, France
Institut de Cancérologie de l'Ouest
RECRUITING

Saint-Herblain, France